ANNEXON, INC. Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized
ANNEXON, INC. (ANNX) reported Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized of 1.53 million shares for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-09.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized · last filed 2021-11-09
- ANNEXON, INC. share-based compensation arrangement by share-based payment award, number of additional shares authorized for the quarter ending 2021-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- ANNEXON, INC. share-based compensation arrangement by share-based payment award, number of additional shares authorized for the quarter ending 2021-06-30 was 0.00 shares.
- ANNEXON, INC. share-based compensation arrangement by share-based payment award, number of additional shares authorized for the quarter ending 2021-03-31 was 1.53M shares.
- ANNEXON, INC. share-based compensation arrangement by share-based payment award, number of additional shares authorized for the quarter ending 2020-12-31 was 0.00 shares.
- ANNEXON, INC. share-based compensation arrangement by share-based payment award, number of additional shares authorized for fiscal 2020 was 4.17M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized 12 month |
|---|---|---|---|---|
| 2021-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | 0.00 shares derived: sum of 2 quarters · filed 2021-11-09 | 1.53M shares 10-Q · filed 2021-11-09 | 1.53M shares derived: sum of 4 quarters · filed 2021-11-09 |
| 2021-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | 1.53M shares 10-Q · filed 2021-08-16 | 1.53M shares derived: sum of 3 quarters · filed 2021-08-16 | 4.75M shares derived: sum of 4 quarters · filed 2021-08-16 |
| 2021-03-31 | 1.53M shares 10-Q · filed 2021-05-17 | 1.53M shares derived: sum of 2 quarters · filed 2021-05-17 | 4.75M shares derived: sum of 3 quarters · filed 2021-05-17 | |
| 2020-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | 3.22M shares derived: sum of 2 quarters · filed 2021-03-25 | 4.17M shares 10-K · filed 2021-03-25 | |
| 2020-09-30 | 3.22M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | 4.17M shares 10-Q · filed 2020-11-16 | ||
| 2020-06-30 | 942.04K shares 10-Q · filed 2020-09-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |